Table 1 Clinical characters of training and validation cohort
| Â | Training cohort | Validation cohort | P value |
|---|---|---|---|
Following time | 15 | 15.07 (11.45–16.32) | 0.05 |
ICI-P | 20/245 (8.16%) | 11/124 (8.87%) | 0.82 |
Age | 66 | 66.38 (65.01–67.75) | 0.78 |
Gender | 110/245 (44.9%) | 56/124 (45.16%) | 0.96 |
BMI | 21.21 (20.74–21.68) | 20.45 (19.85–21.05) | 0.85 |
Smoking history | 46/245 (18.78%) | 30/124 (24.19%) | 0.22 |
Lung cancer | 66/245 (26.94%) | 24/124 (19.35%) | 0.11 |
Lung metastasis | 71/245 (28.98%) | 31/124 (25%) | 0.42 |
Pleural effusion | 44/245 (17.96%) | 19/124 (15.32%) | 0.52 |
PD-1/PD-L1 Antibody | 109/245 (44.49%) | 58/124 (46.77%) | 0.68 |
EGFR-TKI | 41/245 (16.73%) | 6/124 (4.84%) | < 0.01 |
EGFR antibody | 32/245 (13.06%) | 13/124 (10.48%) | 0.47 |
Gemcitabine | 26/245 (10.61%) | 12/124 (9.68%) | 0.78 |
Lung surgery | 32/245 (13.06%) | 11/124 (8.87%) | 0.24 |
Chest radiotherapy | 21/245 (8.57%) | 16/124 (12.9%) | 0.19 |
Non-1st line therapy | 51/245 (20.82%) | 24/124 (19.35%) | 0.74 |
Squamous cancer | 102/245 (41.63%) | 48/124 (38.71%) | 0.59 |
COPD | 31/245 (12.65%) | 20/124 (16.13%) | 0.36 |
Asthma | 23/245 (9.39%) | 9/124 (7.26%) | 0.49 |
IL-6 (pg/ml) | 39.32 (36.28–42.36) | 40.34 (35.76–44.91) | 0.71 |
CRP (mg/L) | 81.81 (76.72–86.89) | 82.75 (75.17–90.33) | 0.84 |
CD3 + T (/ul) | 1924.29 (1872.2–1976.38) | 1911.72 (1839.23–1984.21) | 0.78 |
CD4 + T (/ul) | 879.9 (826.71–933.09) | 878.63 (803.66–953.6) | 0.98 |
CD8 + T (/ul) | 651.44 (599.12–703.75) | 650.07 (576.59–723.55) | 0.98 |
SP-A (ng/ml) | 61.44 (60.04–62.85) | 62.48 (60.32–64.63) | 0.41 |
SP-D (ng/ml) | 259.64(255.46–263.82) | 262.32 (256.67–267.97) | 0.46 |
KL-6 U/ml) | 398.16 (381.57–414.75) | 412.6 (389.79–435.42) | 0.31 |
FVC (%) | 68.56 (67.65–69.47) | 69.48 (68.13–70.83) | 0.25 |
Total | 245 | 124 | Â |